Draft guidance issued last year by the US Food and Drug Administration and the GLP-1 agonist drug boom are among developments signaling a bright future for Click Therapeutics, Inc., leadership says.
Click Therapeutics Anticipates Pharma Will Begin Developing Digital Drugs From Clinical Stage
FDA Draft Guidance And Exploding GLP-1 R&D Create New Horizons For Digital Therapeutics
Leading digital therapeutic maker’s CEO David Benshoof Klein and CMO Shaheen Lakhan discuss outlook on the DTx space, priorities going forward, and what makes Click a standout player in a changing game.
More from Digital Technologies
More from Medtech Insight
• By
Medtech has not yet been spared from the Trump administration’s trade tariffs, which, for UK exporters will be 10% – half the rate applied to EU27 exporters.
• By
Medical devices, diagnostics, and equipment face tariffs announced by President Donald Trump, despite industry pleas for exemption. The tariffs, ranging from 10%-49%, impact most countries trading with the US, potentially hindering innovation and increasing costs in the medtech sector.